ubmslatePT-logo-ubm

PT Mobile Logo

Search form

Topics:

Differential Diagnosis of Psychotic Symptoms: Medical “Mimics”: Page 2 of 2

Differential Diagnosis of Psychotic Symptoms: Medical “Mimics”: Page 2 of 2

Figure. Differential diagnosis of new-onset psychosis
Table 1. Primary or secondary psychosis? Diagnostic mistakes
Table 2. Suggested medical workup for secondary psychosis
Table 3. Medications associated with psychosis
Table 4. Key clinical points in evaluating new-onset psychosis

Seizures. The link between seizures, particularly temporal lobe epilepsy, and psychosis is well established.49 Epidemiological studies have shown a higher rate of schizophrenia in patients with epilepsy and vice versa.50 Psychosis in the setting of seizures can occur during the ictal, postictal, and interictal phases. Ictal psychosis can occur in complex partial or absence status epilepticus. Postictal psychosis emerges close to the seizure and can last several days or weeks, rarely morphing into a chronic psychosis.51,52 Interictal psychosis typically emerges after a decade of poorly treated or poorly responsive epilepsy and is characterized by intense dysphoric affect in addition to psychosis.53 Earlier development of interictal psychosis suggests individual vulnerability as opposed to epilepsy-related damage.54

Confusion, episodic violence, and catatonia are clinical symptoms that should raise suspicion for seizures. If a seizure or epilepsy is suspected, the diagnosis needs to be pursued appropriately. A normal, routine interictal EEG is insufficient to exclude epilepsy. Serial EEGs and optimal lead placement improve the chances of making a diagnosis of epilepsy.55 Frontal lobe seizures, in particular, can be very difficult to diagnose. A high index of suspicion based on history (abrupt onset and cessation of bizarre motor automatisms and vocalizations but little if any postictal confusion) combined with EEG monitoring and alternative electrode placement (eg, pharyngeal leads) can succeed in making this diagnosis.

Space-occupying lesions. Primary or secondary brain tumors can cause psychosis as their first manifestation and should be considered in elderly patients, particularly if there is a persistent headache or other neurological signs, including seizures. However, in the case of “silent” indolent-growing tumors, such as frontal meningiomas, neurological examination findings are often normal.56 Tumor histology is not as important as rapidity of growth and location for the clinical presentation. Temporal lobe location is thought to increase the likelihood of psychosis, although it must be stressed that no lesion location in the brain reliably produces psychosis. Causal attribution of psychosis to incidental neuroimaging findings (eg, cysts or vascular malformations in the temporal lobes) is therefore often unclear. Conditions that increase intracranial pressure, such as normal pressure hydrocephalus, have been associated with psychosis as well.57

Strokes. Rarely, psychosis can be the presenting symptom of a stroke.58 In some cases, stroke-related seizure activity is responsible for the psychosis. The sudden onset of complex visual hallucinations should lead to consideration of 2 lesion-related conditions: peduncular hallucinosis caused by focal midbrain (peduncular) lesions and the Charles Bonnet syndrome following occipital infarction.59 However, in both conditions, causes other than a stroke are possible.

Head injury. A history of head injury is a risk factor for the development of a chronic psychotic syndrome that can be clinically indistinguishable from schizophrenia. Head injury–related psychosis is typically a mostly paranoid-hallucinatory syndrome that develops insidiously several years after injury.60 Patients experiencing psychosis can appear blunted and withdrawn, and it is critical not to ascribe apparent negative symptoms to brain damage but to consider active psychosis. The severity of head injury (as judged by the duration of loss of consciousness) and a family history of psychosis are 2 variables associated with the emergence of psychosis following head injury.61

Demyelinating diseases. Diseases that disrupt the integrity of white matter tracts in the brain can lead to psychosis, likely to be caused by the functional disconnectivity of critical brain regions.62 Demyelinating diseases would be expected to be associated with psychosis if (1) the disease affects the brain as opposed to the brain stem and spinal cord, and (2) the “right” brain regions are disconnected.

Multiple sclerosis, the most common demyelinating disease, is associated with psychosis more often than can be expected by chance, although the rate of psychosis is low.63-65 Inherited leukodystrophies, such as metachromatic leukodystrophy (MLD) and adrenoleukodystrophy (ALD), on the other hand, are associated with a high prevalence of neuropsychiatric symptoms, including psychosis. MLD in particular is associated with a very high rate of psychosis, perhaps as high as 50%.66 MLD is an autosomal recessive disorder caused by a deficiency in the lysosomal enzyme, arylsulfatase A.

ALD is an X-linked disorder in which very-long-chain fatty acids accumulate because of defective peroxisomal oxidation. While inherited leukodystrophies are typically diagnosed in childhood because of their aggressive clinical course with systemic and neurological symptoms, adult-onset cases can present with a predominantly psychiatric picture. The diagnosis of a demyelinating disorder is suggested by abnormal findings on MRI scans. Clinical red flags for inherited leukodystrophies include progressive cognitive decline, other neurological findings (eg, seizures or a neuropathy), or other systemic findings (eg, adrenal insufficiency in patients with ALD).

Basal ganglia disorders. Rare, inherited basal ganglia disorders associated with psychosis include Wilson disease, Huntington disease, and Fahr disease.67 Wilson disease is a disorder of copper metabolism that leads to copper deposits in the liver and the lenticular nucleus of the brain (hence the term “hepatolenticular” degeneration). Since early diagnosis and treatment can prevent irreversible end-organ damage, screening with 24-hour urinary copper and serum ceruloplasmin levels should be considered in psychotic patients, particularly if patients show evidence of liver abnormalities. Kayser-Fleischer rings of the cornea as detected by slitlamp examination are not always present in neuropsychiatric Wilson disease.68

The diagnosis of Huntington disease, an autosomal dominant disorder, is usually not difficult because most patients will have a family history. Psychosis can precede the motor symptoms of Huntington disease and delay its recognition.69,70 While Huntington disease will eventually declare itself clinically, a definite diagnosis can be made earlier with genetic testing.

Fahr disease is characterized by bilateral basal ganglia calcifications and neuropsychiatric symptoms, including psychosis.71 However, basal ganglia calcification can also be an incidental CT finding of unclear significance.

Hallucinations, particularly visual hallucinations, are a common problem associated with Parkinson disease.72 Their etiology is likely to be multifactorial and includes disease severity and dementia as well as treatment with levodopa.73

Nutritional deficiencies. Vitamin B12 deficiency is easily correctable and should be specifically excluded in all patients. Psychosis from vitamin B12 deficiency can predate anemia and the typical spinal symptoms.74,75 Thiamin deficiency is easily correctable as well; therefore, thiamin must be given in the appropriate setting (ie, alcoholism). Niacin deficiency (pellagra) is rare in the United States; symptoms include psychosis in addition to diarrhea, dermatitis, and stomatitis/glossitis.76

Psychosis due to substances

Many toxins, drugs, and medications can cause psychosis without a delirium, although the line between secondary psychosis caused by a substance and toxic psychosis can be difficult to draw. In addition, establishing a causal link between substances and psychosis is not always possible, and in many circumstances of illicit drug use in particular, the exact relationship between psychotic symptoms and the ingested drug requires long-term follow-up. In cases of cannabis use and a psychotic illness, an interaction between drug use and genetic predisposition to schizophrenia is likely.77

Inquiring about all drugs and medications taken (eg, over-the-counter, bought over the Internet, prescribed, nonprescribed, illicit) and an exposure history (occupation and hobbies such as gardening) can provide clues that guide further investigation. Many patients will not volunteer their use of “natural” herbal remedies because they do not appreciate the possibility of adverse reactions. An herbal preparation associated with psychosis is the now-banned ephedra that patients might take for weight loss.78 Patients who subscribe to weight lifting and body building might be taking anabolic steroids. While uncommon and most importantly idiosyncratic (as opposed to dose-related), psychosis is a possible complication of recreational anabolic steroid use.79

The detection of environmental toxin poisoning requires a high index of suspicion. Toxins to consider include carbon monoxide; organophosphates; and heavy metals, particularly arsenic, manganese, mercury, and thallium.80

In many clinical settings, alcohol, sedative-hypnotics, and illicit drugs will be common causes of psychosis. Alcohol and sedative-hypnotics can lead to psychosis during intoxication (rare), during withdrawal, or during a delirium tremens. In persons with long-term alcohol abuse, persistent psychosis in the form of alcoholic hallucinosis or pathological jealousy (Othello syndrome) can develop.81,82 Stimulant drugs (eg, cocaine, methamphetamine) and psychotomimetics (eg, lysergic acid diethylamide [LSD], hallucinogenic mushrooms, phencyclidine [PCP]) as well as cannabis are important drugs that can cause psychosis.

Table 3 lists some medications that have been associated with psychosis.

For a diagnosis of drug-induced psychosis, it is helpful to consider which drugs are prevalent in particular geographic areas and clinical subpopulations. For example, men who have sex with men from urban centers are at risk for using methamphetamine.83 College students might experiment with psychotomimetic party drugs or misuse stimulants obtained (legally and illegally) for the purpose of “cramming” before exams.84 Clinicians need to be cognizant of the drugs included in the urine drug screen because only drugs included in it can potentially be detected.

Summary

Ruling out secondary causes of psychosis is important because the causation of psychosis by a medical disorder or substance can dramatically change management and prognosis. Table 4 summarizes key clinical points to consider when evaluating a patient with new-onset psychosis of unknown etiology. Readers with further interest in secondary psychosis can consult 2 excellent books—The Schizophrenias. A Biological Approach to the Schizophrenia Spectrum Disorders and Secondary Schizophrenia—that cover this topic in more detail.

 

[Editor's Note: Originally presented as an independent educational activity under the direction of CME LLC, this article was published by Psychiatric Times (2010;27[12]:56-61; click here for a pdf of the original article and author's financial disclosure). The ability to receive CME credits has expired. The article is presented here for your reference.]

Pages

References

References:
1. Cutting J. The phenomenology of acute organic psychosis. Comparison with acute schizophrenia. Br J Psychiatry. 1987;151:324-332.
2. Spitzer RL, First MB, Williams JB, et al. Now is the time to retire the term “organic mental disorders.” Am J Psychiatry. 1992;149:240-244.
3. Meagher DJ, Moran M, Raju B, et al. Phenomenology of delirium. Assessment of 100 adult cases using standardised measures. Br J Psychiatry. 2007;190:135-141.
4. Webster R, Holroyd S. Prevalence of psychotic symptoms in delirium. Psychosomatics. 2000;41:519-522.
5. Ballard C, Day S, Sharp S, et al. Neuropsychiatric symptoms in dementia: importance and treatment considerations. Int Rev Psychiatry. 2008;20:396-404.
6. Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022-2030.
7. McKeith IG, Dickson DW, Lowe J, et al; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium [published correction appears in Neurology. 2005;65:1992]. Neurology. 2005;65:1863-1872.
8. Nagahama Y, Okina T, Suzuki N, et al. Classification of psychotic symptoms in dementia with Lewy bodies. Am J Geriatr Psychiatry. 2007;15:961-967.
9. Neumärker KJ. Karl Bonhoeffer and the concept of symptomatic psychoses. Hist Psychiatry. 2001;12(46, pt 2):213-226.
10. De Ronchi D, Bellini F, Cremante G, et al. Psychopathology of first-episode psychosis in HIV-positive persons in comparison to first-episode schizophrenia: a neglected issue. AIDS Care. 2006;18:872-878.
11. Johnstone EC, Cooling NJ, Frith CD, et al. Phenomenology of organic and functional psychoses and the overlap between them. Br J Psychiatry. 1988;153:770-776.
12. Legesse B, Freudenreich O, Murray E, Price B. A case report of confusional psychosis with abrupt onset and rapid resolution of symptoms. Psychosomatics. In press.
13. Caton CL, Drake RE, Hasin DS, et al. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses [published correction appears in Arch Gen Psychiatry. 2005;62:493]. Arch Gen Psychiatry. 2005;62:137-145.
14. Freudenreich O, Schulz SC, Goff DC. Initial medical work-up of first-episode psychosis: a conceptual review. Early Intervent Psychiatry. 2009;31:10-18.
15. Baldessarini RJ, Finklestein S, Arana GW. The predictive power of diagnostic tests and the effect of prevalence of illness. Arch Gen Psychiatry. 1983;40:569-573.
16. Reeves RR, Pinkofsky HB, Kennedy KK. Unreliability of current screening tests for syphilis in chronic psychiatric patients. Am J Psychiatry. 1996;153:1487-1488.
17. Canadian Psychiatric Association. Clinical Practice Guidelines. Treatment of Schizophrenia. Can J Psychiatry. 2005;50(suppl 1):1S-56S.
18. Brownlie BE, Rae AM, Walshe JW, Wells JE. Psychoses associated with thyrotoxicosis—“thyrotoxic psychosis.” A report of 18 cases, with statistical analysis of incidence. Eur J Endocrinol. 2000;142:438-444.
19. Heinrich TW, Grahm G. Hypothyroidism presenting as psychosis: myxedema madness revisited. Prim Care Companion J Clin Psychiatry. 2003;5:260-266.
20. Lehrmann JA, Jain S. Myxedema psychosis with grade II hypothyroidism. Gen Hosp Psychiatry. 2002;24:275-277.
21. Bilgin YM, van der Wiel HE, Fischer HR, De Herder WW. Treatment of severe psychosis due to ectopic Cushing’s syndrome. J Endocrinol Invest. 2007;30:776-779.
22. Saad MF, Adams F, Mackay B, et al. Occult Cushing’s disease presenting with acute psychosis. Am J Med. 1984;76:759-766.
23. Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med. 1999;106:307-310.
24. Benabarre A, Bosch X, Plana MT, et al. Relapsing paranoid psychosis as the first manifestation of pheochromocytoma. J Clin Psychiatry. 2005;66:949-950.
25. Ellencweig N, Schoenfeld N, Zemishlany Z. Acute intermittent porphyria: psychosis as the only clinical manifestation. Isr J Psychiatry Relat Sci. 2006;43:52-56.
26. Tishler PV, Woodward B, O’Connor J, et al. High prevalence of intermittent acute porphyria in a psychiatric patient population. Am J Psychiatry. 1985;142:1430-1436.
27. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375:924-937.
28. Crimlisk HL. The little imitator—porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry. 1997;62:319-328.
29. MacQueen GM, Rosebush PI, Mazurek MF. Neuropsychiatric aspects of the adult variant of Tay-Sachs disease. J Neuropsychiatry Clin Neurosci. 1998;10:10-19.
30. Walterfang M, Fietz M, Fahey M, et al. The neuropsychiatry of Niemann-Pick type C in adulthood. J Neuropsychiatry Clin Neurosci. 2006;18:158-170.
31. The American College of Rheumatology. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599-608.
32. Wright MT. Neuropsychiatric illness in systemic lupus erythematosus: insights from a patient with erotomania and Geschwind’s syndrome. Am J Psychiatry. 2010;167:502-507.
33. Appenzeller S, Cendes F, Costallat LT. Acute psychosis in systemic lupus erythematosus. Rheumatol Int. 2008;28:237-243.
34. Arrojo M, Perez-Rodriguez MM, Mota M, et al. Psychiatric presentation of Hashimoto’s encephalopathy. Psychosom Med. 2007;69:200-201.
35. Wilcox RA, To T, Koukourou A, Frasca J. Hashimoto’s encephalopathy masquerading as acute psychosis. J Clin Neurosci. 2008;15:1301-1304.
36. Foster AR, Caplan JP. Paraneoplastic limbic encephalitis. Psychosomatics. 2009;50:108-113.
37. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327-340.
38. Davies G, Irani SR, Coltart C, et al. Anti-N-methyl-D-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit. Crit Care Med. 2010;38:679-682.
39. Alvarez-Segura M, Villero S, Portugal E, et al. Psychosis induced by decreased CD4+ T cell and high viral load in human immunodeficiency virus infection: a case report. Biol Psychiatry. 2008;64:e3-e4.
40. Friedrich F, Geusau A, Greisenegger S, et al. Manifest psychosis in neurosyphilis. Gen Hosp Psychiatry. 2009;31:379-381.
41. Roelcke U, Barnett W, Wilder-Smith E, et al. Untreated neuroborreliosis: Bannwarth’s syndrome evolving into acute schizophrenia-like psychosis. A case report. J Neurol. 1992;239:129-131.
42. Steadman P. Herpes simplex mimicking functional psychosis. Biol Psychiatry. 1992;32:211-212.
43. Poissy J, Wolff M, Dewilde A, et al. Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis. Clin Microbiol Infect. 2009;15:560-564.
44. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369:499-511.
45. Szucs A, Janszky J, Holló A, et al. Misleading hallucinations in unrecognized narcolepsy. Acta Psychiatr Scand. 2003;108:314-316; dicussion 316-317.
46. Douglass AB, Hays P, Pazderka F, Russell JM. Florid refractory schizophrenias that turn out to be treatable variants of HLA-associated narcolepsy. J Nerv Ment Dis. 1991;179:12-17; discussion 18.
47. Kishi Y, Konishi S, Koizumi S, et al. Schizophrenia and narcolepsy: a review with a case report. Psychiatry Clin Neurosci. 2004;58:117-124.
48. Cao M. Advances in narcolepsy. Med Clin North Am. 2010;94:541-555.
49. Sachdev P. Schizophrenia-like psychosis and epilepsy: the status of the association. Am J Psychiatry. 1998;155:325-336.
50. Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand. 2004;110:207-220.
51. Adachi N, Ito M, Kanemoto K, et al. Duration of postictal psychotic episodes. Epilepsia. 2007;48:1531-1537.
52. Devinsky O. Postictal psychosis: common, dangerous, and treatable. Epilepsy Curr. 2008;8:31-34.
53. Blumer D, Wakhlu S, Montouris G, Wyler AR. Treatment of the interictal psychoses. J Clin Psychiatry. 2000;61:110-122.
54. Adachi N, Akanuma N, Ito M, et al. Two forms of déjà vu experiences in patients with epilepsy. Epilepsy Behav. 2010;18:218-222.
55. Salinsky M, Kanter R, Dasheiff RM. Effectiveness of multiple EEGs in supporting the diagnosis of epilepsy: an operational curve. Epilepsia. 1987;28:331-334.
56. Madhusoodanan S, Danan D, Moise D. Psychiatric manifestations of brain tumors: diagnostic implications. Expert Rev Neurother. 2007;7:343-349.
57. Lying-Tunell U. Psychotic symptoms in normal-pressure hydrocephalus. Acta Psychiatr Scand. 1979;59:415-419.
58. Chemerinski E, Robinson RG. The neuropsychiatry of stroke. Psychosomatics. 2000;41:5-14.
59. Mocellin R, Walterfang M, Velakoulis D. Neuropsychiatry of complex visual hallucinations. Aust N Z J Psychiatry. 2006;40:742-751.
60. Fujii D, Ahmed I. Characteristics of psychotic disorder due to traumatic brain injury: an analysis of case studies in the literature. J Neuropsychiatry Clin Neurosci. 2002;14:130-140.
61. Sachdev P, Smith JS, Cathcart S. Schizophrenia-like psychosis following traumatic brain injury: a chart-based descriptive case-control study. Psychol Med. 2001;31:231-239.
62. Friston KJ, Frith CD. Schizophrenia: a disconnection syndrome? Clin Neurosci. 1995;3:89-97.
63. Patten SB, Svenson LW, Metz LM. Psychotic disorders in MS: population-based evidence of an association. Neurology. 2005;65:1123-1125.
64. Feinstein A. The neuropsychiatry of multiple sclerosis. Can J Psychiatry. 2004;49:157-163.
65. Figved N, Klevan G, Myhr KM, et al. Neuropsychiatric symptoms in patients with multiple sclerosis. Acta Psychiatr Scand. 2005;112:463-468.
66. Hyde TM, Ziegler JC, Weinberger DR. Psychiatric disturbances in metachromatic leukodystrophy. Insights into the neurobiology of psychosis. Arch Neurol. 1992;49:401-406.
67. Yu V. Considering inherited, basal ganglia diseases in the differential diagnosis of first-episode psychosis. Psychiatry Weekly. http://www.psychweekly.com/aspx/article/articledetail.aspx?articleid=37. Accessed November 1, 2010.
68. Makharia GK, Nandi B, Garg PK, Tandon RK. Wilson’s disease with neuropsychiatric manifestations and liver disease but no Kayser-Fleischer ring. J Clin Gastroenterol. 2002;35:101-102.
69. Amann B, Sterr A, Thoma H, et al. Psychopathological changes preceding motor symptoms in Huntington’s disease: a report on four cases. World J Biol Psychiatry. 2000;1:55-58.
70. Ribaï P, Nguyen K, Hahn-Barma V, et al. Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients. Arch Neurol. 2007;64:813-819.
71. Lauterbach EC, Cummings JL, Duffy J, et al. Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington’s, Wilson’s, and Fahr’s diseases. A report of the ANPA Committee on Research. American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 1998;10:249-266.
72. Fénelon G, Soulas T, Zenasni F, de Langavant LC. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25:755-759.
73. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2001;70:734-738.
74. Evans DL, Edelsohn GA, Golden RN. Organic psychosis without anemia or spinal cord symptoms in patients with vitamin B12 deficiency. Am J Psychiatry. 1983;140:218-221.
75. Herr KD, Norris ER, Frankel BL. Acute psychosis in a patient with vitamin B(12) deficiency and coincident cervical stenosis. Psychosomatics. 2002;43:234-236.
76. Prakash R, Gandotra S, Singh LK, et al. Rapid resolution of delusional parasitosis in pellagra with niacin augmentation therapy. Gen Hosp Psychiatry. 2008;30:581-584.
77. McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry. 2010;67:440-447.
78. Maglione M, Miotto K, Iguchi M, et al. Psychiatric effects of ephedra use: an analysis of Food and Drug Administration reports of adverse events. Am J Psychiatry. 2005;162:189-191.
79. Pope HG Jr, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry. 1988;145:487-490.
80. Freudenreich O. Secondary schizophrenia. In: Psychotic Disorders. Philadelphia: Lippincott Williams & Wilkins; 2008:37-45.
81. Soyka M. Psychopathological characteristics in alcohol hallucinosis and paranoid schizophrenia. Acta Psychiatr Scand. 1990;81:255-259.
82. Soyka M, Naber G, Völcker A. Prevalence of delusional jealousy in different psychiatric disorders: an analysis of 93 cases. Br J Psychiatry. 1991;158:549-553.
83. Shoptaw S, Reback CJ. Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction. 2007;102(suppl 1):130-135.
84. Freudenreich O, Cather C, Holt D. Stimulant misuse in college for “pseudo-attention deficit disorder” during schizophrenia prodrome. Am J Psychiatry. 2006;163:2019.
85. Freudenreich O, Holt DJ, Cather C, et al. The evaluation and management of patients with first-episode schizophrenia: a selective, clinical review of diagnosis, treatment, and prognosis. Harv Rev Psychiatry. 2007;15:189-211.
86. Freudenreich O, Nejad S, Francis A, et al. In: Levenson JL, ed. Psychosis, Mania and Catatonia in the Medically Ill. Arlington, VA: American Psychiatric Publishing. In press.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.